Reuters logo
6 months ago
BRIEF-Astellas terminates agreement with UMN Pharma for cell culture based influenza vaccine programs
January 10, 2017 / 8:31 AM / 6 months ago

BRIEF-Astellas terminates agreement with UMN Pharma for cell culture based influenza vaccine programs

1 Min Read

Jan 10 (Reuters) - Astellas Pharma Inc :

* Says co terminates agreement with UMN Pharma Inc , for the co-development and Astellas' exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan

Source text in Japanese: goo.gl/7j7Ed7

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below